Substituted pyrimidines for inhibiting Raf kinase activity

US9920048B2 · kind B2 · utility

Assignees

• Millennium Pharmaceuticals, Inc. · US
• Sunesis Pharmaceuticals, Inc. · US

Inventors

• Weirong Chen · Waltham, US
• Jennifer Cossrow · San Mateo, US
• Lloyd Charles Franklin · Hamilton, US
• Bing Guan · Needham, US
• John H. Jones · Seattle, US
• Gnanasambandam Kumaravel · Westford, US
• Benjamin S. Lane · Chelsea, US
• Adam Littke · Boston, US
• Alexey A. Lugovskoy · Woburn, US
• Hairuo Peng · Needham, US
• Noel Powell · Westford, US
• Brian Raimundo · San Francisco, US
• Hiroko Tanaka · Foster City, US
• Jeffrey Vessels · Marlborough, US
• Thomas Andrew Wynn · Lexington, US
• Zhili Xin · Lake Bluff, US

Key dates

• Filing date: Dec 15, 2016
• Grant date: Mar 20, 2018
• Expiry date: Dec 15, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/65583
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I:or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.